원료의약품 CDMO 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 분자 유형별, 합성법별, 약물 유형별, 워크플로우별, 용도별, 지역별, 경쟁별(2020-2030년)
Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Molecule Type, By Synthesis, By Drug Type, By Workflow, By Application, By Region and Competition, 2020-2030F
상품코드:1881530
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 원료의약품(API) CDMO 시장은 2024년에 9,698만 달러로 평가되었으며, 2030년까지 CAGR 6.1%로 성장하여 1억 3,835만 달러에 달할 것으로 예측됩니다.
원료의약품(API) 위탁개발생산기관(CDMO)은 계약에 따라 API의 종합적인 개발 및 제조 서비스를 제공하여 제약회사에 원료의약품 합성, 공정 최적화, 확장 가능한 생산, 규제 준수를 지원합니다. 시장 성장은 주로 제약 R&D 투자 증가, 새로운 치료법을 필요로 하는 만성질환의 전 세계적 확산, 약물 분자의 복잡성 증가에 기인합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
9,698만 달러
시장 규모 : 2030년
1억 3,835만 달러
CAGR : 2025-2030년
6.1%
가장 빠르게 성장하는 부문
종양학
최대 시장
북미
주요 시장 촉진요인
탄탄한 의약품 R&D 파이프라인과 지속적인 신약 승인은 세계 원료의약품(API) CDMO 시장을 크게 견인하고 있습니다. 새로운 치료법에 대한 업계의 막대한 투자는 전문적인 API 개발 및 제조 전문성을 필요로 합니다.
주요 시장 과제
세계 원료의약품 CDMO 시장의 성장을 저해하는 가장 큰 과제 중 하나는 외주 생산 공정에 대한 충분한 투명성과 통제력을 유지하는 것입니다. 이러한 어려움은 제조 문제의 원인을 파악하고, 복잡한 공급망을 관리하며, 계약 제약사에게 중요한 지식의 손실로 이어질 수 있습니다.
주요 시장 동향
생물학적 제제 및 첨단 치료법 생산의 아웃소싱 증가는 세계 원료의약품 CDMO 시장에서 중요한 추세입니다. 제약기업들이 단클론항체, 세포 치료제, 유전자 치료제 등 복잡한 바이오의약품에 집중함에 따라, 개발 및 제조에 필요한 전문 노하우와 인프라는 외부 파트너십을 필요로 하는 경우가 증가하고 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
분자 유형별(저분자, 고분자)
합성 방법별(바이오테크놀러지, 합성)
의약품 유형별(신약, 제네릭 의약품)
워크플로우별(임상, 상업)
용도별(순환기, 종양학, 안과, 신경학, 정형외과, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 원료의약품 CDMO 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 원료의약품 CDMO 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
Cambrex Corporation
Thermo Fisher Scientific, Inc.
Recipharm AB
Corden Pharma International GmbH
Samsung Biologics Co., Ltd.
Lonza Group Ltd.
Siegfried Holding AG
Piramal Pharma Limited
AbbVie Inc.
Catalent, Inc.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Active Pharmaceutical Ingredients CDMO Market, valued at USD 96.98 Million in 2024, is projected to experience a CAGR of 6.1% to reach USD 138.35 Million by 2030. An Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides comprehensive development and manufacturing services for APIs on a contract basis, assisting pharmaceutical firms with drug substance synthesis, process optimization, scalable production, and regulatory compliance. The market's growth is primarily driven by increasing pharmaceutical research and development investments, the escalating global prevalence of chronic diseases necessitating new therapies, and the growing complexity of drug molecules.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 96.98 Million
Market Size 2030
USD 138.35 Million
CAGR 2025-2030
6.1%
Fastest Growing Segment
Oncology
Largest Market
North America
Key Market Drivers
The robust pharmaceutical research and development pipeline, along with consistent new drug approvals, significantly drives the Global Active Pharmaceutical Ingredients CDMO Market. Substantial industry investment in novel therapies necessitates specialized API development and manufacturing expertise. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical R&D expenditure reached USD 204 billion in 2023, underscoring this commitment to innovation and growth. This sustained investment fuels demand for CDMOs capable of supporting complex early-stage development through commercial scale production. The global API manufacturing landscape features geographically diversified capabilities, crucial for supply chain resilience. For instance, according to the Pacific Forum, in 2022, India housed 18% of global API manufacturing facilities, demonstrating the importance of specialized centers in meeting worldwide demand.
Key Market Challenges
A significant challenge impeding the growth of the Global Active Pharmaceutical Ingredients CDMO Market involves maintaining adequate transparency and control over outsourced production processes. This difficulty can lead to struggles in pinpointing the origin of manufacturing issues, navigating complex supply chains, and potentially causing a loss of critical knowledge for the contracting pharmaceutical company. Without clear visibility and stringent control, pharmaceutical firms face heightened risks regarding product quality and regulatory compliance.
Key Market Trends
The rising outsourcing of biologics and advanced therapies production represents a pivotal trend in the Global Active Pharmaceutical Ingredients CDMO Market. As pharmaceutical companies increasingly focus on complex biopharmaceuticals, including monoclonal antibodies, cell, and gene therapies, the specialized expertise and infrastructure required for their development and manufacturing often necessitate external partnerships. These advanced modalities demand sophisticated facilities, stringent quality control, and specialized technical personnel that many pharmaceutical companies prefer to outsource to dedicated CDMOs. The U. S. Food and Drug Administration (FDA) reported that in 2023, the Center for Biologics Evaluation and Research (CBER) approved 22 new Biologics License Applications (BLAs), nearly doubling the approvals from 2021 and 2022, underscoring the expanding pipeline in this segment.
Key Market Players
Cambrex Corporation
Thermo Fisher Scientific, Inc.
Recipharm AB
Corden Pharma International GmbH
Samsung Biologics Co., Ltd.
Lonza Group Ltd.
Siegfried Holding AG
Piramal Pharma Limited
AbbVie Inc.
Catalent, Inc.
Report Scope:
In this report, the Global Active Pharmaceutical Ingredients CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Active Pharmaceutical Ingredients CDMO Market, By Molecule Type:
Small Molecule
Large Molecule
Active Pharmaceutical Ingredients CDMO Market, By Synthesis:
Biotech
Synthetic
Active Pharmaceutical Ingredients CDMO Market, By Drug Type:
Innovative
Generics
Active Pharmaceutical Ingredients CDMO Market, By Workflow:
Clinical
Commercial
Active Pharmaceutical Ingredients CDMO Market, By Application:
Cardiology
Oncology
Ophthalmology
Neurology
Orthopedic
Other
Active Pharmaceutical Ingredients CDMO Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Active Pharmaceutical Ingredients CDMO Market.
Available Customizations:
Global Active Pharmaceutical Ingredients CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Active Pharmaceutical Ingredients CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Molecule Type (Small Molecule, Large Molecule)
5.2.2. By Synthesis (Biotech, Synthetic)
5.2.3. By Drug Type (Innovative, Generics)
5.2.4. By Workflow (Clinical, Commercial)
5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Active Pharmaceutical Ingredients CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Molecule Type
6.2.2. By Synthesis
6.2.3. By Drug Type
6.2.4. By Workflow
6.2.5. By Application
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Molecule Type
6.3.1.2.2. By Synthesis
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Workflow
6.3.1.2.5. By Application
6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Molecule Type
6.3.2.2.2. By Synthesis
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Workflow
6.3.2.2.5. By Application
6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Molecule Type
6.3.3.2.2. By Synthesis
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Workflow
6.3.3.2.5. By Application
7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Molecule Type
7.2.2. By Synthesis
7.2.3. By Drug Type
7.2.4. By Workflow
7.2.5. By Application
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Molecule Type
7.3.1.2.2. By Synthesis
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Workflow
7.3.1.2.5. By Application
7.3.2. France Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Molecule Type
7.3.2.2.2. By Synthesis
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Workflow
7.3.2.2.5. By Application
7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Molecule Type
7.3.3.2.2. By Synthesis
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Workflow
7.3.3.2.5. By Application
7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Molecule Type
7.3.4.2.2. By Synthesis
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Workflow
7.3.4.2.5. By Application
7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Molecule Type
7.3.5.2.2. By Synthesis
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Workflow
7.3.5.2.5. By Application
8. Asia Pacific Active Pharmaceutical Ingredients CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Molecule Type
8.2.2. By Synthesis
8.2.3. By Drug Type
8.2.4. By Workflow
8.2.5. By Application
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Molecule Type
8.3.1.2.2. By Synthesis
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Workflow
8.3.1.2.5. By Application
8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Molecule Type
8.3.2.2.2. By Synthesis
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Workflow
8.3.2.2.5. By Application
8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Molecule Type
8.3.3.2.2. By Synthesis
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Workflow
8.3.3.2.5. By Application
8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Molecule Type
8.3.4.2.2. By Synthesis
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Workflow
8.3.4.2.5. By Application
8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Molecule Type
8.3.5.2.2. By Synthesis
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Workflow
8.3.5.2.5. By Application
9. Middle East & Africa Active Pharmaceutical Ingredients CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Molecule Type
9.2.2. By Synthesis
9.2.3. By Drug Type
9.2.4. By Workflow
9.2.5. By Application
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Molecule Type
9.3.1.2.2. By Synthesis
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Workflow
9.3.1.2.5. By Application
9.3.2. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Molecule Type
9.3.2.2.2. By Synthesis
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Workflow
9.3.2.2.5. By Application
9.3.3. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Molecule Type
9.3.3.2.2. By Synthesis
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Workflow
9.3.3.2.5. By Application
10. South America Active Pharmaceutical Ingredients CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Molecule Type
10.2.2. By Synthesis
10.2.3. By Drug Type
10.2.4. By Workflow
10.2.5. By Application
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Molecule Type
10.3.1.2.2. By Synthesis
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Workflow
10.3.1.2.5. By Application
10.3.2. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Molecule Type
10.3.2.2.2. By Synthesis
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Workflow
10.3.2.2.5. By Application
10.3.3. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Molecule Type
10.3.3.2.2. By Synthesis
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Workflow
10.3.3.2.5. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis
